Free Trial

Quest Diagnostics (DGX) Competitors

Quest Diagnostics logo
$161.46 +0.14 (+0.09%)
(As of 10:15 AM ET)

DGX vs. LH, DVA, CHE, CRVL, RCM, AMED, MD, AMN, CCRN, and NTRA

Should you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Laboratory Co. of America (LH), DaVita (DVA), Chemed (CHE), CorVel (CRVL), R1 RCM (RCM), Amedisys (AMED), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), and Natera (NTRA).

Quest Diagnostics vs.

Laboratory Co. of America (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

Laboratory Co. of America received 83 more outperform votes than Quest Diagnostics when rated by MarketBeat users. Likewise, 63.93% of users gave Laboratory Co. of America an outperform vote while only 49.21% of users gave Quest Diagnostics an outperform vote.

CompanyUnderperformOutperform
Laboratory Co. of AmericaOutperform Votes
615
63.93%
Underperform Votes
347
36.07%
Quest DiagnosticsOutperform Votes
532
49.21%
Underperform Votes
549
50.79%

Laboratory Co. of America pays an annual dividend of $2.88 per share and has a dividend yield of 1.2%. Quest Diagnostics pays an annual dividend of $3.00 per share and has a dividend yield of 1.9%. Laboratory Co. of America pays out 55.7% of its earnings in the form of a dividend. Quest Diagnostics pays out 40.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 13 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Laboratory Co. of America presently has a consensus target price of $255.92, suggesting a potential upside of 8.31%. Quest Diagnostics has a consensus target price of $164.58, suggesting a potential upside of 1.93%. Given Laboratory Co. of America's stronger consensus rating and higher probable upside, equities analysts clearly believe Laboratory Co. of America is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Laboratory Co. of America
0 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.80
Quest Diagnostics
0 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50

95.9% of Laboratory Co. of America shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 0.9% of Laboratory Co. of America shares are held by insiders. Comparatively, 0.8% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Laboratory Co. of America has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Quest Diagnostics has a net margin of 8.82% compared to Laboratory Co. of America's net margin of 3.43%. Laboratory Co. of America's return on equity of 15.27% beat Quest Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Laboratory Co. of America3.43% 15.27% 7.13%
Quest Diagnostics 8.82%15.25%6.92%

Quest Diagnostics has lower revenue, but higher earnings than Laboratory Co. of America. Quest Diagnostics is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$12.71B1.55$418M$5.1745.70
Quest Diagnostics$9.25B1.95$854M$7.4421.70

In the previous week, Quest Diagnostics had 4 more articles in the media than Laboratory Co. of America. MarketBeat recorded 19 mentions for Quest Diagnostics and 15 mentions for Laboratory Co. of America. Laboratory Co. of America's average media sentiment score of 1.21 beat Quest Diagnostics' score of 0.95 indicating that Laboratory Co. of America is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Laboratory Co. of America
11 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quest Diagnostics
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Laboratory Co. of America beats Quest Diagnostics on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DGX vs. The Competition

MetricQuest DiagnosticsMedical laboratories IndustryMedical SectorNYSE Exchange
Market Cap$18.02B$3.07B$5.07B$19.90B
Dividend Yield1.86%11.18%4.99%3.49%
P/E Ratio21.709.0389.5636.63
Price / Sales1.95215.431,224.8017.98
Price / Cash12.65406.7839.4521.28
Price / Book2.633.206.974.58
Net Income$854M-$32.86M$119.04M$985.06M
7 Day Performance2.93%0.59%-1.78%0.51%
1 Month Performance9.54%-0.23%-3.59%1.13%
1 Year Performance20.27%25.97%31.64%24.80%

Quest Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DGX
Quest Diagnostics
4.9045 of 5 stars
$161.46
+0.1%
$164.58
+1.9%
+19.7%$18.02B$9.25B21.7048,000Analyst Downgrade
LH
Laboratory Co. of America
4.7655 of 5 stars
$236.28
-0.7%
$255.92
+8.3%
+12.7%$19.76B$12.71B46.0167,000Positive News
DVA
DaVita
4.2959 of 5 stars
$162.41
+0.6%
$161.80
-0.4%
+65.5%$13.32B$12.14B17.4170,000Positive News
CHE
Chemed
4.9019 of 5 stars
$556.76
+0.7%
$641.50
+15.2%
-4.5%$8.38B$2.26B27.9815,087Ex-Dividend
Positive News
CRVL
CorVel
1.4222 of 5 stars
$356.74
+0.4%
N/A+66.0%$6.11B$795.31M75.424,870Positive News
RCM
R1 RCM
3.181 of 5 stars
$14.31
flat
$15.41
+7.7%
N/A$6.04B$2.25B0.0030,000News Coverage
AMED
Amedisys
3.9441 of 5 stars
$90.01
+0.0%
$100.67
+11.8%
-4.1%$2.95B$2.24B35.7119,000
MD
Pediatrix Medical Group
3.5872 of 5 stars
$14.40
-0.6%
$16.10
+11.8%
+61.0%$1.24B$1.99B0.005,170Analyst Forecast
News Coverage
AMN
AMN Healthcare Services
4.7519 of 5 stars
$24.79
0.0%
$48.33
+95.0%
-63.0%$943.76M$3.79B17.973,585
CCRN
Cross Country Healthcare
4.6207 of 5 stars
$10.14
-0.7%
$18.50
+82.4%
-52.3%$333.81M$2.02B-204.1610,831Short Interest ↓
NTRA
Natera
2.8052 of 5 stars
$166.02
-1.1%
$140.59
-15.3%
+206.4%$21.92B$1.08B0.003,293Analyst Forecast

Related Companies and Tools


This page (NYSE:DGX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners